Haemostatic management of intraoral bleeding in patients with congenital deficiency of alpha2-plasmin inhibitor or plasminogen activator inhibitor-1.
Haemostatic management of intraoral bleeding was investigated in patients with congenital alpha2-plasmin inhibitor (alpha2-PI) deficiency or congenital plasminogen activator inhibitor- 1 (PAI-1) deficiency. When extracting teeth from patients with congenital alpha2-PI deficiency, we advocate that 7.5-10 mg kg(-1) of tranexamic acid be administered orally every 6 h, starting 3 h before surgery and continuing for about 7 days. For the treatment of continuous bleeding, such as post-extraction bleeding, 20 mg kg(-1) of tranexamic acid should be administered intravenously, and after achieving local haemostasis 7.5 mg kg(-1) of tranexamic acid should be administered orally every 6 h for several days. In addition, when treating haematoma caused by labial or gingival laceration or buccal or mandibular contusion, haemostasis should be achieved by administering 7.5-10 mg kg(-1) of tranexamic acid every 6 h. Tranexamic acid can also be used for haemostatic management of intraoral bleeding in patients with congenital PAI-1 deficiency, but is less effective when compared with use in patients with congenital alpha2-PI deficiency. Continuous infusion of 1.5 mg kg(-1) h(-1) of tranexamic acid is necessary for impacted tooth extraction requiring gingival incision or removal of local bone.
Morimoto
Y
Y
Department of Dental Anesthesiology, Graduate School of Dentistry, Osaka University, Suita, Japan. ysn-mori@dent.osaka-u.ac.jp
Yoshioka
A
A
Imai
Y
Y
Takahashi
Y
Y
Minowa
H
H
Kirita
T
T
D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D006488:Hemostasis, Surgical; D006801:Humans; D006472:Oral Hemorrhage / Q000209:etiology* / Q000601:surgery*; D017395:Plasminogen Activator Inhibitor 1 / Q000172:deficiency*; D000979:alpha-2-Antiplasmin / Q000172:deficiency*
D017395:Plasminogen Activator Inhibitor 1; D000979:alpha-2-Antiplasmin